Before New Year's, the bar will be raised for how well a diabetes drug can perform when Eli Lilly displays the first phase III results from the future hope tirzepatide.
That is, at least, the hope that Eli Lilly's Global Brand Development Leader James Croaning has. He is in charge of the development of tirzepatide in Eli Lilly's diabetes business.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.